Goldman Sachs Starts Regeneron Pharma (REGN) at Buy, Sees 23% Upside

Goldman Sachs initiates coverage on Regeneron Pharma (NASDAQ: REGN) with a Buy and $144 price target, suggesting 23% upside. The firm said Eylea is on its way to blockbuster status.

"The key driver for shares is recently launched drug, Eylea, for a variety of eye diseases that lead to vision loss," the analyst said. "We anticipate continued robust uptake of Eylea (GS WW peak sales of $4bn, $2.3bn in US), which we project will propel the company to sustainable profitability in 4Q12."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $116.62 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
• Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy
• JPMorgan Resumes SanDisk (SNDK) at Overweight